News Quantified

MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]

3 Top Growth Stocks to Buy in the First Half of 2026 [Yahoo! Finance]

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at Cowen Inc.

-1.2%

BEAT

12.0%

BEAT

9.8%

BEAT

Raymond James Financial, Inc.

Leerink Partners

Form 4 Mirum Pharmaceuticals, For: Jan 15 Filed by: Ramasastry Saira

Form 144 Mirum Pharmaceuticals, Filed by: Ramasastry Saira

Form 8-K Mirum Pharmaceuticals, For: Jan 12

Form 4 Mirum Pharmaceuticals, For: Dec 31 Filed by: Peetz Christopher

Form 4 Mirum Pharmaceuticals, For: Dec 22 Filed by: Ramasastry Saira

Top News Gainers

12/13 Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast 111.0%

3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%

3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%

1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%

12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%

4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%

4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%

4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%

2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%

4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%

Top News Decliners

3/17 Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha] -10.7%

1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%

1/6 Form S-1 Mirum Pharmaceuticals, -6.0%

12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%

4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%

1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%

8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%

8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%

12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%

9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day